Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.57 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.57 |
| ▸ | NOD2 | Q9HC29 | 4/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.51 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2345728 | 0.89 | NOD2 (0.52) | PTGDR2PTGDRNOD2NOD1ELANE | |
| SCHEMBL2345364 | 0.88 | ELANE (0.48) | PTGDR2PTGDRNOD2NOD1ELANE | |
| SCHEMBL2344679 | 0.88 | NOD2 (0.44) | PTGDR2PTGDRNOD2NOD1MAPT | |
| SCHEMBL12392496 | 0.87 | NOD2 (0.48) | PTGDR2PTGDRNOD2NOD1ELANE | |
| SCHEMBL2343252 | 0.87 | HTR6 (0.50) | PTGDR2PTGDRNOD2NOD1ELANE | |
| SCHEMBL2925186 | 0.84 | NOD2 (0.55) | NOD2NOD1ELANEMAPT | |
| SCHEMBL2346812 | 0.80 | NOD2 (0.52) | PTGDR2PTGDRNOD2NOD1ELANE | |
| SCHEMBL2351246 | 0.80 | NOD2 (0.51) | PTGDR2PTGDRNOD2NOD1ELANE | |
| SCHEMBL2346815 | 0.78 | NOD2 (0.49) | PTGDR2PTGDRNOD2NOD1ELANE | |
| SCHEMBL6002068 | 0.77 | NOD2 (0.48) | PTGDR2PTGDRNOD2NOD1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008295-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | disclosed |
| EP-1534695-B1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20100041652-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-02-18 | — | — | US | disclosed |
| US-20090186871-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2009-07-23 | — | — | US | disclosed |
| US-7560546-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1534695-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20080008708-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-10 | — | — | US | disclosed |
| EP-1534268-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060128783-A1 | Tyrosine kinase inhibitors | DINSMORE CHRISTOPHER J | 2006-06-15 | — | — | US | disclosed |
| US-20050261496-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2005-11-24 | — | — | US | disclosed |
| EP-1534268-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| EP-1534695-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004014851-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014300-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128783-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, JAK2 | PTGDR2 1182/4885PTGDR 1047/4885NOD2 2323/4885 |
| US-20050261496-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | PTGDR2 1665/4885PTGDR 1319/4885NOD2 2119/4885 |
| US-20080008708-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, JAK2 | PTGDR2 1182/4885PTGDR 1047/4885NOD2 2323/4885 |
| US-20090186871-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | PTGDR2 1665/4885PTGDR 1319/4885NOD2 2119/4885 |
| US-20100041652-A1 | TYROSINE KINASE INHIBITORS | ABL1, ERBB2, JAK2 | PTGDR2 1182/4885PTGDR 1047/4885NOD2 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.